Novel Immunotherapies for Myasthenia Gravis.

Immunotargets Ther · 2023 · PMC10082579 · PMID 37038596

Europe PMC DOI

hedged sentence

0.0698

closest p · 1.4× alpha

0.0698

boldest claim

The sentences

failed to attain significancep=0.0698so close (0.05 < p ≤ 0.1)

26 The study failed to attain significance for the primary endpoint (mean rank of 56.6 vs 68.3, p=0.0698).

also in 59 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.